Kaleido BioSciences Inc. is planning to raise up to $100 million in an IPO on Nasdaq.

The Lexington, Mass.-based biotechnology company, whose pipeline includes medicines for infections caused by drug-resistant bacteria, heart and kidney diseases, and diarrhea, plans to list its shares on the Nasdaq Global Select Market under the symbol KLDO.

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Canaccord Genuity LLC are the underwriters of the IPO and will have an option to buy additional shares in the offering.